Abstract
Background Myocarditis has emerged as a rare but lethal Immune checkpoint inhibitor (ICI)-associated toxicity. However, the exact mechanism for ICI related myocarditis remains underexplored; and the specific therapeutic targets is still lacking. In this study, we used scRNA-seq to characterize the transcriptomic profiles of single cells from the peripheral blood mononuclear cell (PBMC) of ICI related myocarditis during fulminant myocarditis and disease recovery.
Methods PBMC samples were taken from the patient during fulminant ICI related myocarditis and after disease remission. Cells were isolated from blood samples by density gradient centrifugation over Ficoll-Paque. Single-cell RNA sequencing with 10X genomics was performed. Subpopulation determination, functional analysis, single-cell trajectory and cell-cell interaction analysis were carried out afterwards.
Results We presented the altered landscape of immune cells and differential genes in ICI related myocarditis during the disease activity and remission using scRNA-seq. Substantial immune cell composition and intercellular communication were found to be altered. Monocyte, NK cell as well as B cell subpopulations contributed to the regulation of innate immunity and inflammation in ICI related myocarditis. T cell subpopulations highly expressed genes associated with PD-1 inhibitor resistance and hyper-progressor. At last, the intercellular communication in ICI related myocarditis was significantly dysregulated.
Conclusion By identifying altered pathways and highlighting a catalog of marker genes, this study has revealed the diversity of cellular populations in ICI related myocarditis, marked by their distinct transcriptional profiles and biological functions. Our investigation would shed light on the pathophysiological mechanism and potential therapeutic targets of ICI related myocarditis in continuous exploration.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by National Natural Science Foundation of China (No. 82170464, 82100477), National Key R&D Program of China (2019YFA0802300, 2018YFC1311505), Key Research and Development Program of Shaanxi (No. 2021KWZ-25, S2020-YF-GHMS-0014, 2020GXLH-Y-015), Central University Basic Science Foundation of China (119132971000056); and the Clinical Research Award of the First Affiliated Hospital of Xi'an Jiaotong University, China (No. XJTU1AF-CRF-2018-025，XJTU1AF-CRF-2017-006).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethnic committee of the First Affiliated Hospital of Xian Jiaotong University gave ethical approval of this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The authors declare no potential conflicts of interest.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
ABBREVIATIONS AND ACRONYMS
- ICI
- Immune checkpoint inhibitor
- PBMC
- Peripheral blood mononuclear cell
- PD-1
- Programmed Death Molecule 1
- PD-L1
- Programmed Cell Death 1 Ligand 1
- TCR
- T cell receptor
- BCR
- B cell receptor
- CDR
- Complementary determining region
- irAEs
- immune-related adverse events
